- A +

Events › 2016

29 - 30Nov.2016

GenSight will attend Cell Therapy Manufacturing & Gene Therapy congress in Amsterdam. 

On Day 1, Tuesday 29 November, Time: 11:15 - 11:50, Stream: Cell, Gene and Immunotherapy Manufacturing, Process Optimization and Analytics, Nitza Thomasson, Chief Preclinical Officer, will give an oral presentation on : COMPARABILITY STUDY SET UP WHEN CHANGING OF MANUFACTURER : GUIDELINE, STUDY AND AGENCY FEEDBACK

On Day 1, Tuesday 29 November, Time: 11:50 - 12:25, Stream: Clinical Development for Cell, Gene and Immunotherapies, Jean Philippe Combal, COO, will giva an oral presentation on : FROM ACADEMIA / CRO THEN TO CMO : PRODUCT CHARACTERIZATION VERSUS POTENTIAL PRODUCT EVOLUTION

15 - 16Nov.2016

Stifel Healthcare Conference 2016 - New York, NY, USA

Bernard Gilly, Chief Executive Officer and Thomas Gidoin, Chief Financial Officer will present at the Stifel Healthcare Conference 2016 in New York, NY, USA on Tuesday, November 15, 2016, at 3:45 pm ET, and host investor meetings.

07 - 09Nov.2016

GenSight attended BioEurope in Cologne, Germany and met with potential partners willing to understand and better know the progress of our programs. 

Isabelle Scarabin, Business Development Manager, presented the company on Tuesday 8 November, 9:30 am, in the Rare and Orphan Diseases track, room Rheinsaal 1 on level 2

03 - 04Nov.2016

GenSight attended 2nd Annual Cell & Gene Therapy Congress in London, UK. Anne Douar, Project Director, gave an oral presenation on “Translational development of GS030, an optogenetic therapy for retinal dystrophies combining a stimulating medical device” on Day 1, 5.50-6.20 pm. 

18 - 21Oct.2016

GenSight attended the European Society of gene and Cell Therapy congress (ESGCT) in Florence, Italy. 

Jean-Philippe Combal, Chief Operating Officer, gave an oral presentation on Wednesday 19 October, 11:00 am, Session 2b:  Eye stem cell and gene therapy.

OR04  - One-year follow-up study results after IntravitrealrAAV2/2-ND4 (GS010) injection in patients with vision loss due to G11778A ND4 Leber Hereditary Optic Neuropathy.

Wednesday 19 October, Poster Session 1

Poster #P247 - From Non-Human Primates to Patients: Relationship between ocular inflammation and immune responses following intravitreal injection of rAAV2/2-ND4 (GS010), will be also presented. 

05 - 08Oct.2016

GenSight attended the European Association for Vision and Eye Research, EVER congress, in Nice, France. 

On Wednesday, October 5, 2016, at 16:50, in session - Neuro-ophthalmology and paediatric ophthalmology, Dr C. Vignal-Clermont, Fondation Ophtalmologique A de Rothschild, Neuro Ophthalmology, Paris, France, gave an oral presentation on : Relationship between immune response and ocular inflammation after intravitreal injection of rAAV2/2–ND4 (GS010) in Leber Hereditary Optic Neuropathy (LHON) patients. 

ID number: 1553.

Abstract : https://www.ever.be/Congress/2016/Programme.aspx

05 - 07Oct.2016

GenSight participated to the Cell&Gene Meeting on the mesa11th Annual Scientific Program and 6th Annual Partnering Forum, organized by ARM.

Jean Philippe Combal, COO, presented the company on Day 1 at 3:00pm.

21 - 22Sept.2016

GenSight attended Cell&Gene Therapy Europe in Berlin, Germany.

On Wednesday 21, 2016, in Stream 2 ATMP R&D strategy & clinical updates, Jean Philippe Combal, COO, gave an oral presentation in session Preclinical-clinical translation: minimizing timeframes, maximising insight, at 2.30pm, on:  "MTS for LHON and Optogenetics for RP: Translational pathways from animal to clinical trials".

04 - 07May2016

GenSight gave several oral presentations at ASGCT, Washington DC (US), on its lead products for the treatment of retinal degenerative diseases that lead to blindness. 

- GS010 aiming at treating LHON, a rare mitochondrial genetic disease

Phase I Gene Therapy Preliminary Clinical Results for treatment of ND4 Leber Hereditary Optic Neuropathy with rAAV2-2-ND4. Session: Gene Therapy for Neurosensory Diseases (Room: Washington 1-2. Presentation Time: Thursday May 5, 4:30pm - 4:45pm. Abstract number: 267)

Relationship between immune responses and ocular inflammation: what is learnt from intravitreal injection of rAAV2/2–ND4 (GS010) in non-human primates and Leber Hereditary Optic Neuropathy (LHON) patients. Session: Immunological Aspects of Gene Therapy I: AAV Vectors  (Room Washington 5-6, Presentation time: Wednesday May 4, 2016 5:00pm - 5:15pm, Abstract number: 83)

- GS030 based on optogenetics to treat RP

Optogenetic engineering of retinal ganglion cells with AAV2.7m8-ChrimsonR-tdTomato is well tolerated and induces functional responses to light in non-human primates. Session: Gene Therapy for Neurosensory Diseases (Room: Washington 1-2. Presentation Time: Thursday May 5, 4:45pm - 5:00pm. Abstract number: 268)

 

01 - 05May2016

GenSight was invited to ARVO in Seattle (Wash), US.

Scott Urestky, MD, Neuro-Ophthalmology, Director of Clinical Development at GenSight, gave a talk on "Allotopic Gene Therapy for ND4 Leber Hereditary Optic Neuropathy with rAAV2/2-ND4 (GS010): From Pre-Clinical Development to Phase III".

The company presented also several posters on both its lead products as well as an oral presentation on its optogenetics product GS030

- GS010 aiming at treating LHON, a rare mitochondrial genetic disease

Intravitreal injection of rAAV2/2–ND4 (GS010): immune responses and ocular inflammation in non-human primates and patients with Leber Hereditary Optic Neuropathy (LHON). Session: Gene editing and therapies (Presentation time: Sun, May 01, 3:15pm - 5:00pm Abstract Number: 1177 - C0027)

- GS030 based on optogenetics to treat RP

Optogenetic engineering of retinal ganglion cells with AAV2.7m8-ChrimsonR-tdTomato in combination with an event-based camera photostimulation device. Session: Diseases and Protection (Room Tahoma 5, TCC. Presentation Time: Wed, May 04, 5:00pm - 5:15pm. Abstract Number: 5260)

Optogenetic visual restoration using ChrimsonR: Photoactivation below safety radiation limit in retinal ganglion cell populations from non-human primates. (Abstract Number: 598 - B0071)

Optogenetic visual restoration using ChrimsonR: Photocurrent analysis in primate retinal ganglion cells by using two-photon guided patch-clamp recording. (Abstract Number: 599 - B0072)

Optogenetic visual restoration using ChrimsonR: Validation in degenerative rodent models, rd1 and P23H. (Abstract Number: 600 - B0073)

Optogenetic visual restoration using ChrimsonR: Biophysical properties study in HEK cells using patch clamp recordings. (Abstract Number: 601 - B0074)

All poster will be presented at the session “Visual Disease Models and Restoration”, Sun, May 01, 1:30pm - 3:15pm

22Mar.2016

GenSight has been selected to present at the 4th annual Cell & Gene Therapy Investor Day, organized by the Alliance for Regenerative Medecine.

It is a full-day conference combining discussions between key opinion leaders, top analysts and senior executives in addition to presentations by the field’s most promising companies. Bernard Gilly, CEO of GenSight, will present the company. 

27 - 03Feb. - Mar.2016

GenSight participated to NANOS 42nd Annual Meeting in Tucson (AZ), US.

Dr Catherine Vignal, Head chief at the Rothschild Ophthalmological Foundation, MD in XV-XX Hospital, Paris, will give a talk on " Recombinant AAV2 Containing the Wild-Type ND4 Gene (rAAV2/2-ND4) is an Experimental Gene Therapy for Vision Loss in LHON Due to the ND4 Mitochondrial Mutation: Phase I/IIa Safety Investigation Results and Upcoming Pivotal Phase III Efficacy Studies ".

25 - 27Jan.2016

GenSight participated to Phacilitate Cell&Gene Therapy in Washington DC. 

On Monday January 25, 2016, Jean Philippe Combal, COO at GenSight, gave a talk on " Retinal Ganglion Cells Targeting with LHON & Optogenetics for RP : Translational development up to Pivotal trials " at 3.25 pm within the track " CELL & GENE THERAPY CLINICAL UPDATES: OPHTHALMOLOGY ". 

11 - 15Jan.2016

GenSight was in Francisco during the JP Morgan 34th Annual Healthcare Conference and will meet with a numerous partners and companies, willing to know about our promising products under development and their innovative technologies, to prevent sight loss and restore vision.